Two-level concomitant degenerative olisthesis patients saw estimated fusion rates of 63 percent with i-FACTOR compared to 18 percent with allograft. i-FACTOR bone graft is a biologic bone graft that utilizes a synthetic small peptide as an attachment factor intended to stimulate the natural bone healing.
IFACTOR BIOLOGIC TRIAL
Those patients with one-level concomitant degenerative olisthesis accomplished estimated fusion rates of 40 percent with i-FACTOR compared to 21 percent with allograft.ģ. A prospective, randomized, controlled trial of the i-FACTOR biologic bone graft from Cerapedics has shown a 97. putty i-FACTOR Peptide Enhanced Bone Graft 1.0cc Syringe REF 700-010, PUTTY. This unique combination creates a surface-bound Attract, Attach, Activate mechanism of action that enhances the body’s natural bone healing process. At one-year postoperative follow-up, researchers found a 50 percent fusion rate using i-FACTOR versus a 20 percent fusion rate using allograft.Ģ. i-FACTOR Bone Graft is the only biologic bone graft made of a small peptide, P-15 Osteogenic Cell Binding Peptide, bound to an anorganic bone mineral (ABM). The patients underwent non-instrumented lumbar posterolateral spine surgery with either i-FACTOR Peptide Enhanced Bone Graft or allograft.ġ. i-FACTOR bone graft is the only biologic bone graft that combines a unique anorganic bone mineral (ABM) and small peptide (P-15) to act as an attachment factor for specific integrins on. The study involved 98 patients aged 60 or older who suffered from lumbar spinal stenosis or concomitant degenerative olisthesis. Andersen, MD, of Middelfart Hospital in Denmark, reported results from the IVANOS study investigating Cerapedics' i-FACTOR Peptide Enhanced Bone Graft.
Patient Experience + Marketing Virtual Forum i-FACTOR Bone Graft is the only biologic bone graft made of a synthetic small peptide (P-15) bound to an anorganic bone mineral (ABM). i-FACTOR biologic bone graft features synthetic small peptide (P-15) technology that supports bone growth through cell attachment and osteoblast differentiation.Cerapedics is now actively involved in introducing the i-FACTOR Bone Graft technology platform into the rapidly expanding market for osteobiologic products. Since approval, ABM/P-15 has been used in an estimated 500,000 procedures.įrom these roots, Cerapedics has reformulated the (ABM/P-15) product and branded it i-FACTOR Peptide Enhanced Bone Graft to capture the unique “attachment factor” mechanism of action. Prior to joining iFactor, Manuel spent 15 years, consulting clients with McKinsey and as a banker for JPMorgan, gaining a deep understanding of the financial ecosystem. Ortega B, Gardner C, Roberts S, Chung A, Wang JC, Buser Z.
i-FACTOR Bone Graft comes in a Putty or as a FLEX with purified silk fibers. As an engineered product, P-15 quantity and viability remain consistent from lot to lot. It remains the only dental bone graft substitute with FDA approved claims of superiority over demineralized bone matrix (DBM) allograft and alloplasts. Ceramic Biologics for Bony Fusion-a Journey from First to Third Generations. i-FACTOR Bone Graft is a peptide bone matrix ( PBM) a composite bone substitute consisting of a synthetic collagen fragment (P-15) bound to calcium phosphate particles. The product received PMA approval in 1999 based on the results of two prospective multi-center investigations. The first P-15 enhanced bone graft substitute was developed for use in the oral cavity by CeraMed Dental – the precursor to Cerapedics – under the leadership of Andrew J.
IFACTOR BIOLOGIC SKIN
This novel (ABM/P-15) combination acts as an attachment factor for osteogenic cells. Tech and healthcare giant GE (NYSE:GE) put some skin in Cerapedics and its i-FACTOR bone graft, funding a 9 million venture debt financing round for the Colorado-based company. Our lead technology platform (i-FACTOR Peptide Enhanced Bone Graft) is the only biologic bone graft that uses a unique small peptide attachment factor (P-15) bound to anorganic bone mineral (ABM).
0 kommentar(er)
